CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Genetic testing	$ 248,873	$ 439,400	$ 921,610	$ 1,342,947
Other	47,125	32,751	153,651	145,365
Total revenue	295,998	472,151	1,075,261	1,488,312
Cost of revenue	323,136	358,578	985,732	1,115,095
Gross profit	(27,138)	113,573	89,529	373,217
Operating expenses:
Research and development	411,902	242,142	978,970	666,839
Selling, general and administrative	1,413,702	1,305,583	4,631,718	4,338,245
Amortization of intangibles	19,414	23,525	58,242	70,575
Total operating expenses	1,845,018	1,571,250	5,668,930	5,075,659
Loss from operations	(1,872,156)	(1,457,677)	(5,579,401)	(4,702,442)
Other income (expense):
Interest income	0	911	222	4,511
Interest expense	(153,354)	0	(456,311)	0
Total other income (expense)	(153,354)	911	(456,089)	4,511
Loss before income taxes	(2,025,510)	(1,456,766)	(6,035,490)	(4,697,931)
Benefit for income taxes	0	0	0	0
Net loss	$ (2,025,510)	$ (1,456,766)	$ (6,035,490)	$ (4,697,931)
Basic and diluted net loss per common share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.04)
Weighted average common shares outstanding, basic and diluted (in shares)	172,841,047	122,548,292	172,788,286	122,515,671